CCNDBP1 antibody
Principal name
CCNDBP1 antibody
Alternative names for CCNDBP1 antibody
DIP1, GCIP, HHM, MAID, Cyclin-D1-binding protein 1, Grap2 and cyclin-D-interacting protein, Human homolog of Maid
Ncbi ID
9606, NP_036274, NP_036274.3, NM_012142, NP_034891.2, NM_010761, NM_001013204
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Paraffin Sections (P)
Background of CCNDBP1 antibody
- Kit Component:
- - KN302812G1, Ccndbp1 gRNA vector 1 in pCas-Guide vector
- KN302812G2, Ccndbp1 gRNA vector 2 in pCas-Guide vector
- KN302812D, donor vector containing left and right homologous arms and Luciferase-Puro functional cassette
- GE100003, scramble sequence in pCas-Guide vector - CRISPR Manual:
- CRISPR/CAS9 Genome Editing Manual
Western Blot analysis of CCNDBP1 expression in transfected 293T cell line by CCNDBP1 monoclonal antibody (M02), clone 3B7.Lane 1: CCNDBP1 transfected lysate(40.3 KDa).Lane 2: Non-transfected lysate.
Western Blot analysis of CCNDBP1 expression in transfected 293T cell line (H00023582-T01) by CCNDBP1 MaxPab polyclonal antibody.Lane 1: CCNDBP1 transfected lysate(39.6 KDa).Lane 2: Non-transfected lysate.
CCNDBP1 MaxPab polyclonal antibody. Western Blot analysis of CCNDBP1 expression in K-562.
Human Small Intestine; WB Suggested Anti-CCNDBP1 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:62500. Positive Control: Human Small Intestine; CCNDBP1 antibody - middle region (ARP55414_P050) in Human Small Intestine cells using Western Blot
Human Liver; WB Suggested Anti-CCNDBP1 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:312500. Positive Control: Human Liver; CCNDBP1 antibody - middle region (ARP55415_P050) in Human Liver cells using Western Blot
AP31958PU-N CCNDBP1 antibody staining of Human Placenta lysate at 0.3 µg/ml (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Immunohistochemical staining of human colon shows strong nuclear positivity in glandular cells.This validation was performed by Protein Atlas and the presentation of data is for informational purposes only.
ELISA: CCNDBP1 Antibody
WB Suggested Anti-CCNDBP1 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 312500; Positive Control: Human Liver
WB Suggested Anti-CCNDBP1 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 62500; Positive Control: Human Small Intestine
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AP31958PU-N | CCNDBP1 (322-333) antibody |
||||||
 |
Goat | Aff - Purified | Bov, Can, Hu, Por | E, WB |
0.1 mg /
€380.00
|
||
| OriGene Technologies GmbH | |||||||
OriGene recommends this product for Western blotting. |
|||||||
| TA590422 | CCNDBP1 antibody |
||||||
| Rabbit Polyclonal CCNDBP1 Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu | E, P |
0.1 mg /
€409.00
|
|
| OriGene Technologies, Inc. | |||||||
 +1 additional image |
|||||||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP760039 | CCNDBP1 (full length, N-term HIS tag, transcript variant 1) |
||||
| Recombinant protein of human cyclin D-type binding-protein 1 (CCNDBP1), transcript variant 1, full length, with N-terminal HIS tag, expressed in E.Coli, 50ug | |||||
 |
Human | > 80 % Preparation: . Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
E. coli |
50 µg /
€205.00
|
|
| OriGene Technologies, Inc. | |||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY415955 | CCNDBP1 overexpression lysate |
|
 |
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR206788L2V | Lenti ORF particles, Ccndbp1 (GFP-tagged ORF) - Rat cyclin D-type binding-protein 1 (Ccndbp1), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| RR206788L1V | Lenti ORF particles, Ccndbp1 (Myc-DDK-tagged ORF) - Rat cyclin D-type binding-protein 1 (Ccndbp1), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||